Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials

5Citations
Citations of this article
51Readers
Mendeley users who have this article in their library.

Abstract

Background: Most patients receiving docetaxel-based chemotherapy for castration resistant prostate cancer (CRPC) will eventually progress, and the optimal interventions for these patients are controversial. The objective of our study is to evaluate the clinical efficacy and safety of pharmacological interventions for CRPC patients progressing after docetaxel-based chemotherapy. Methods: A systematic review and Bayesian network meta-analysis of the literature was carried out according to standard methods. Major electronic databases including PubMed, Web of Science and Embase were searched until Jan 2017. Hazard ratios (HRs) and odds ratios (ORs) with corresponding 95% credible intervals (CrIs) were used to estimate the association. Results: 17 Randomized Controlled Trials (RCTs) comprising 14 different interventions with 12347 patients were enrolled. Compared with control arms, Abiraterone Acetate (HR: 0.70, 95%CrI: 0.63-0.79), Cabazitaxel (HR: 0.70, 95%CrI: 0.51-0.95) and Enzalutamide (HR: 0.63, 95%CrI: 0.53-0.75) presented similar benefits in term of OS. Enzalutamide showed superiority over PFS and PSA response with a highest probability to rank 1. Moreover, sensitivity analysis showed that Abiraterone Acetate (HR: 0.71, 95%CrI: 0.63-0.78) exhibited the most efficacious intervention of being rank 1 in term of OS compared with control arms, followed by Cabazitaxel and Cetuximab. On the other hand, Abiraterone Acetate (OR: 0.86, 95%CrI: 0.35-2.03) presented no significant toxicities compared with control arms. Conclusions: Our results demonstrated that Abiraterone Acetate might be the optimal intervention for CRPC patients after docetaxel failure with acceptable tolerability. Future well-designed RCTs and systematic reviews are needed to validate these findings.

References Powered by Scopus

Bias in meta-analysis detected by a simple, graphical test

43038Citations
N/AReaders
Get full text

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

26010Citations
N/AReaders
Get full text

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

23837Citations
N/AReaders
Get full text

Cited by Powered by Scopus

NOTCH signaling pathway and non-coding RNAs in cancer

27Citations
N/AReaders
Get full text

177 lu-psma radioligand therapy is favorable as third-line treatment of patients with metastatic castration-resistant prostate cancer. A systematic review and network meta-analysis of randomized controlled trials

11Citations
N/AReaders
Get full text

Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review

6Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Zhao, Y., Huang, H., Chen, C., Liu, H., Liu, H., Su, F., … Huang, J. (2018). Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials. Journal of Cancer, 9(4), 690–701. https://doi.org/10.7150/jca.22365

Readers over time

‘18‘19‘20‘21‘22‘23‘24‘250481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

48%

Lecturer / Post doc 6

29%

Researcher 5

24%

Readers' Discipline

Tooltip

Medicine and Dentistry 19

68%

Business, Management and Accounting 4

14%

Pharmacology, Toxicology and Pharmaceut... 4

14%

Biochemistry, Genetics and Molecular Bi... 1

4%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free
0